Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and
chemotherapy have both demonstrated efficacy in recurrent metastatic non-small-cell lung …

Lung cancer is the leading cause of cancer deaths worldwide. Targeting the epidermal
growth factor receptor (EGFR) has played a central role in advancing non-small-cell lung …

Background: Erlotinib is approved as treatment for metastatic non-small-cell lung cancer
(NSCLC), following failure of initial therapy. Studies to define patients that derive maximal …

BACKGROUND: Randomized trials of advanced non-small cell lung cancer (NSCLC) have
demonstrated the activity of docetaxel in second-line and erlotinib in the third-line setting …

Abstract Treatment of non-small-cell lung cancer is dependent on disease stage. For
patients with metastasis or locally advanced disease, the importance of finding therapeutic …

Purpose This study investigated whether sequential administration of erlotinib and
chemotherapy improves clinical outcomes versus chemotherapy alone in unselected …

Background: Erlotinib is a standard of treatment for metastatic non-small-cell lung cancer
after failure of initial therapy. Patient selection based on clinical factors is under discussion …

BACKGROUND. Erlotinib is an orally available, reversible inhibitor of epidermal growth
factor receptor (EGFR) with a proven survival advantage for patients with locally advanced …

Treatment with third-generation chemotherapy agents improves survival and quality of life of
patients with non-small-cell lung cancer (NSCLC). Despite these favorable outcomes, most …

A majority of patients with lung cancer present with advanced disease: approximately 30%
with locally advanced disease and 45% with metastatic disease. The prognosis for these …